Precision Biosciences Inc
Precision Biosciences Inc (DTIL) Unusual Options Activity Today
DTIL options volume power reached 1.16x on the previous trading day. The highest reading was on the $10 CALL expiring 2027-01-15.
Read more
Checking DTIL unusual options activity helps you spot when traders are making outsized bets on Precision Biosciences Inc before the broader market catches on. Precision Biosciences Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor DTIL unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching DTIL unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking DTIL unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and DTIL unusual options flow data becomes especially valuable around earnings, product launches, and macro events.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.
The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Catalysts rarely arrive without a footprint, and DTIL unusual options activity is often where that footprint shows up first. Our scanner tracks Precision Biosciences Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at DTIL unusual options volume on the call side or chasing put sweeps, Precision Biosciences Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.
| 2.50 | 1.15 | 6.00 | 3.58 | 43% | 0 | 0 | — |
| 5.00 | — | 4.90 | 4.90 | 1,000% | 0 | 1 | 0.00% |
| 7.50 | — | 4.90 | 4.90 | 1,000% | 0 | 144 | 0.00% |
| 10.00 | — | 4.90 | 4.90 | 1,000% | 0 | 0 | — |
| 12.50 | — | 4.90 | 4.90 | 1,000% | 0 | 0 | — |
| 2.50 | — | 4.90 | 4.90 | 1,000% | 0 | 0 | — |
| 5.00 | — | 4.90 | 4.90 | 1,000% | 0 | 0 | — |
| 7.50 | — | 4.90 | 4.90 | 799% | 0 | 1 | 0.00% |
| 10.00 | 1.50 | 6.10 | 3.80 | 137% | 0 | 0 | — |
| 12.50 | 4.00 | 8.70 | 6.35 | 209% | 0 | 0 | — |
As of September 29, 2026
Spot unusual options activity before it moves
Track DTIL options flow across every expiration, filter by volume power, and find the setups with abnormal activity before the trade is gone.
Start your 14-day free trial→